» Articles » PMID: 2986987

VLA-1: a T Cell Surface Antigen Which Defines a Novel Late Stage of Human T Cell Activation

Overview
Journal Eur J Immunol
Date 1985 May 1
PMID 2986987
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The VLA-1 protein complex defines a previously undescribed very late stage of activated T cell differentiation, following either alloantigen or mitogen activation. This protein appears after 2-3 weeks of activation, considerably later than the early T cell activation antigens such as the interleukin 2 (IL 2) receptor, transferrin receptor, 4F2 antigen, T10 and HLA-DR, and has therefore been termed very late antigen-1 (VLA-1). Unlike the IL 2 receptor, VLA-1 expression does not require restimulation with antigen, and in fact, VLA-1 expression was high on T cells that had lost their IL 2 receptors. Expression of VLA-1 was found on all or nearly all long-term-activated T cells including T4+ and T8+ clones, bulk cultures, long-term T cells from adults and newborns and long-term T cells maintained in pure or crude IL 2 preparations. VLA-1 was also found on HTLV-1 infected T cell populations. Immunoprecipitation experiments confirmed that the VLA-1 protein complex (210 000/130 000 Mr) can be co-expressed with another protein complex called VLA-2 (165 000/130 000 Mr) on the same T cell clones. However, co-expression was not obligatory because in some long-term cultures little or no VLA-2 was present relative to VLA-1. Because VLA-1 defines a novel late stage of T cell activation, being present on all or most all types of long-term activated T cells, and not on any other cell types in peripheral blood, it has unique potential as a marker for activated T cells in vivo and may provide a clue towards elucidating novel long-term T cell functions or growth requirements of this late stage of T cell differentiation.

Citing Articles

Integrins in Health and Disease-Suitable Targets for Treatment?.

Klaus T, Hieber C, Bros M, Grabbe S Cells. 2024; 13(3.

PMID: 38334604 PMC: 10854705. DOI: 10.3390/cells13030212.


Targeting integrin pathways: mechanisms and advances in therapy.

Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z Signal Transduct Target Ther. 2023; 8(1):1.

PMID: 36588107 PMC: 9805914. DOI: 10.1038/s41392-022-01259-6.


The Molecular Interaction of Collagen with Cell Receptors for Biological Function.

Elango J, Hou C, Bao B, Wang S, Mate Sanchez de Val J, Wenhui W Polymers (Basel). 2022; 14(5).

PMID: 35267698 PMC: 8912536. DOI: 10.3390/polym14050876.


Cytoskeletal prestress: The cellular hallmark in mechanobiology and mechanomedicine.

Chowdhury F, Huang B, Wang N Cytoskeleton (Hoboken). 2021; 78(6):249-276.

PMID: 33754478 PMC: 8518377. DOI: 10.1002/cm.21658.


VLA-1 Binding to Collagen IV Controls Effector T Cell Suppression by Myeloid-Derived Suppressor Cells in the Splenic Red Pulp.

Eckert I, Ribechini E, Jarick K, Strozniak S, Potter S, Beilhack A Front Immunol. 2021; 11:616531.

PMID: 33584706 PMC: 7873891. DOI: 10.3389/fimmu.2020.616531.